1. streetstock43rac
2. lea4582et
3. zpc9909
4. mmagwitz
5. imaflygirlpilot
1.lea4582et 01/18/2018
Pricing of $475 Million Public Offering
2.streetstock43rac 01/08/2018
a little news - Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value
3.zpc9909 02/14/2018
Misses EPS loss estimates by $0.15 and misses on revenues
4.lea4582et 01/17/2018
Agios Announces Proposed Offering of Common Stock - up to $400 million
5.lea4582et 06/03/2018
Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent
6.streetstock43rac 04/11/2018
Credit Suisse sets PT at $95
7.mmagwitz 01/18/2018
Stock rebounded and did better than I thought, down only 3%
8.streetstock43rac 05/17/2018
Company will present new clinical data from its IDH Programs at ASCO
9.zpc9909 02/14/2018
Agios Reports Fourth Quarter and Full Year 2017 Financial Results
10.imaflygirlpilot 02/15/2018
FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW